Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.45 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6535537 | 0.86 | GPR119 (0.49) | GPR119ALOX5APFEN1HRH2HRH1 | |
| SCHEMBL4326309 | 0.86 | GPR119 (0.49) | GPR119ALOX5APFEN1HRH2HRH1 | |
| SCHEMBL14045135 | 0.86 | GPR119 (0.49) | GPR119ALOX5APFEN1HRH2HRH1 | |
| SCHEMBL2889380 | 0.86 | GPR119 (0.49) | GPR119ALOX5APFEN1HRH2HRH1 | |
| SCHEMBL4314692 | 0.86 | GPR119 (0.49) | GPR119ALOX5APFEN1HRH2HRH1 | |
| SCHEMBL6535308 | 0.86 | GPR119 (0.49) | GPR119ALOX5APFEN1HRH2HRH1 | |
| SCHEMBL6535548 | 0.86 | GPR119 (0.49) | GPR119ALOX5APFEN1HRH2HRH1 | |
| SCHEMBL604147 | 0.85 | FPR3 (0.51) | GPR119ALOX5APFEN1HRH2HRH1 | |
| SCHEMBL6195438 | 0.85 | ALOX5AP (0.52) | GPR119ALOX5APFEN1HRH2HRH1 | |
| SCHEMBL4312709 | 0.85 | GPR119 (0.48) | GPR119ALOX5APFEN1HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728032-B2 | Phenoxymethylalkyne inhibitors of LTA4H for treating inflammation | DECODE GENETICS EHF (IS) | 2010-06-01 | — | — | US | disclosed |
| US-20080090839-A1 | PHENOXYMETHYLALKYNE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2008-04-17 | — | — | US | disclosed |
| WO-2008019284-A1 | PHENOXYMETHYLALKYNE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090839-A1 | PHENOXYMETHYLALKYNE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTB4R2 | GPR119 1290/4885ALOX5AP 17/4885FEN1 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.